Stocktoria

Evommune, Inc. EVMN

NYSE · stock · Pharmaceutical Preparations · website · IPO 2025-11-06

Evommune, Inc. statistics & valuation

Market cap$906.9M
P / S69.8×
P / B4.4×
Net margin-529.8%
Return on equity-33.5%
FCF margin-589.8%
Return on capital-39.2%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-954.40% -529.80% 20242025
Gross margin (%)
20242025
Operating margin (%)
-1000.20% -623.60% 20242025
Return on equity (%)
-33.50% 20242025
Shares outstanding
1.6M 31.5M 20242025
Net debt ($)
20242025
Share buybacks ($)
20242025
Return on assets (%)
-87.80% -30.60% 20242025
Free cash flow margin (%)
-832.60% -589.80% 20242025
Debt / equity (×)
20242025
EPS ($)
-$45.29 -$11.22 20242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024
Operating margin-623.6%-1000.2%
Net margin-529.8%-954.4%
FCF margin-589.8%-832.6%
Return on assets-30.6%-87.8%
Return on equity-33.5%46.3%
Current ratio8.572.64

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.